Published in final edited form as:

Bioorg Med Chem Lett. 2013 September 1; 23(17): 4817–4819. doi:10.1016/j.bmcl.2013.06.080.

Investigation into the functional impact of the vancomycin C-ring aryl chloride

Joseph R. Pinchman and Dale L. Boger*

Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

Abstract

A vancomycin aglycon analogue that possesses a reduced C-ring and an intact E-ring chloride was prepared and its antimicrobial activity towards *S. aureus* and binding affinity to model cell wall ligands were established. Comparison of the derivative with a series of vancomycin aglycon analogues that possess and lack the chloro substituents on the aryl C- and E-rings defines the impact and further refines the role the C-ring chloride plays in promoting both target binding affinity and binding selectivity for D-Ala-D-Ala and its impact on antimicrobial activity.

Keywords

Vancomycin; Vancomycin analogues; Borylation

Vancomycin (**1**) and structurally related glycopeptide natural products have proven to be invaluable antibiotics over the past fifty years.¹ Most recently, vancomycin is prescribed as the drug of last resort for the treatment resistant Gram-positive bacterial infections, including methicillin-resistant *Staphylococcus aureus* (MRSA).² Vancomycin disrupts bacterial cell wall biosynthesis by binding to the peptide terminus D-Ala-D-Ala found in peptidoglycan precursors through a network of five hydrogen bonds, thereby inhibiting cell wall cross-linking.^{2,3} Alarming, vancomycin-resistant bacteria have emerged which are able to overcome this mode of action. In the more prevalent resistant bacterial strains, VanA and VanB, the D-Ala-D-Ala terminus is remodeled to D-Ala-D-Lac resulting in a 1000-fold decrease in antibiotic binding affinity and an accompanying 1000-fold loss of antimicrobial activity.^{2–5} Additionally, several resistant strains (VanC, VanE, VanG) have been found to possess an altered D-Ala-D-Ser peptide terminus.^{6–8} Although not as severe, these bacteria display reduced sensitivity to vancomycin antimicrobial activity, resulting from a reduced binding affinity for D-Ala-D-Ser.^{5,9}

Our efforts to overcome vancomycin bacterial resistance have enlisted both total and semi-synthesis studies and have provided several vancomycin analogues that are effective against resistant bacteria.^{10–12} As a result of these studies, we have a strong interest in

© 2013 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1-858-784-7522; fax: +1-858-784-7550; boger@scripps.edu.

Supporting Information **Available**. Full experimental details and characterization for all final compounds are provided in the supporting information. This material is available free of charge via the internet at <http://www.sciencedirect.com/science/journal/0960894X>.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

understanding the intricacies of the binding properties of vancomycin.¹³ In a recent report, we disclosed synthetic efforts capable of selective Pd(0)-catalyzed conversion of the E-ring aryl chloride in vancomycin aglycon derivatives to a boronic acid, permitting the synthesis of alternatively substituted E-ring analogues to probe the impact of this characteristic feature of the glycopeptides antibiotics.¹⁴ Many E-ring aryl chloride substitution analogues were well tolerated and it was the presence, but not the nature, of a substituent on the E-ring that was important for maintaining binding affinity for a terminal D-Ala-D-Ala model peptide and antimicrobial activity. Herein, we disclose an initial study on the impact and role of the C-ring aryl chloride through the synthesis and evaluation of the reduced C-ring vancomycin aglycon possessing the E-ring aryl chloride (**3**) and its comparison with a series of vancomycin aglycon analogues (**2–5**) that possess and lack the chloro substituents on the C and E-aryl rings (Figure 1, Table 1).

Eremomycin, a naturally occurring glycopeptide also possesses a vancomycin heptapeptide scaffold with a reduced C-ring and intact E-ring aryl chloride.^{1,15} However due to the presence of alternative amino-sugars on the periphery of the molecule, comparisons to vancomycin do not provide a clear indication as to the role of the C-ring chloride in binding and antimicrobial activity. Our studies on the selective borylation of the *N*-Boc vancomycin aglycon (**6**) revealed that a major byproduct from the reaction was the reduced C-ring aryl chloride aglycon possessing an E-ring aryl boronic acid (**7**, Figure 2).¹⁴ With this intermediate in hand, copper(II)-mediated chlorination and *N*-Boc deprotection provided the desired vancomycin aglycon analogue **3**, capable of direct assessment of only the impact of the C-ring aryl chloride.

For comparison, a complete series of vancomycin aglycon analogues that possess and lack the aryl chloride substituents was assembled. Compounds **4** and **5** which lacked the E-ring chloride and both C- and E-ring aryl chlorides, respectively, were prepared as previously described by Harris through hydrogenation of vancomycin aglycon.¹⁶

The antimicrobial activity of vancomycin and the vancomycin aglycon analogues **2–5** against sensitive *S. aureus* were obtained according to a standard microtiter plate-based antimicrobial assay (Table 2).^{11,17} Ligand binding studies were performed according to the procedure of Nieto and Perkins with the ligands *N,N'*-Ac₂-L-Lys-D-Ala-X (X = D-Ala, D-Ser, Gly, D-Phe) and the results are summarized in Table 2.¹⁸ These ligands represent known (X = Gly) and additional possible vancomycin binding sites in the bacterial cell wall of resistant bacteria (X = D-Ser).

Removal of just the C-ring aryl chloride with **3** led to a >8-fold drop in activity against sensitive *S. aureus* compared to the vancomycin aglycon. This loss in activity was more substantial than the decrease in activity seen upon the selective removal of the E-ring aryl chloride in **4**. The difference in antimicrobial activity can be explained through ligand binding studies with *N,N'*-Ac₂-L-Lys-D-Ala-D-Ala, which revealed that selective removal of the C-ring chloride with **3** led to an approximate 4-fold loss in binding, whereas the selective E-ring chloride removal with **4** led to a smaller 2-fold decrease in binding affinity. Interestingly, the loss of binding for **3** and **4** for D-Ala-D-Ala are additive and explain the poorer binding observed for the analogue **5**, lacking both the C- and E-ring chlorides.

For the model D-Ala-D-Ser ligand, analogue **3** was slightly more effective at binding than the aglycon. Nevertheless, the binding affinity was reduced ca. 30-fold for both analogues. The lower binding with D-Ala-D-Ser accounts for the decreased antimicrobial activity of vancomycin on VanC, VanE, and VanG bacterial strains. For D-Ala-Gly, analogue **3** was 2-fold less effective than that of the vancomycin aglycon which is a slightly smaller decrease compared to that seen with D-Ala-D-Ala (ca. 3-fold). For the larger D-Ala-D-Phe ligand, it was

possible that the removal of the C-ring aryl chloride would enable better binding due to decreased steric constraints. However, both **2** and **3** showed equally reduced binding towards the model D-Ala-D-Phe ligand.

These observations further refine the role of the C-ring aryl chloride in target binding selectivity and binding affinity. Its presence helps define the vancomycin binding pocket and increase binding affinity for terminal D-Ala-D-Ala ligands over alternative bacterial cell wall binding sites and its impact is larger than that of the E-ring chloride. Additionally, the comparative binding studies of **2** and **3** with model cell wall ligands provide a valuable insight into and starting point for evaluating C-ring analogues replacing the chloride with alternative substituents.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the financial support of the National Institute of Health (CA041101).

References and notes

- Nagarajan, R., editor. Glycopeptide antibiotics. Marcel Dekker Inc.; New York: 1994.
- Kahne D, Leimkuhler C, Lu W, Walsh C. Chem Rev. 2005; 105:425. [PubMed: 15700951] Hubbard BK, Walsh CT. Angew Chem, Int. 2003; 42:730.
- Perkins HR. Pharmacol Ther. 1982; 16:181. [PubMed: 6752974] Williams DH, Bardsley B. Angew Chem, Int. 1999; 38:1172.
- Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Biochemistry. 1991; 30:10408. [PubMed: 1931965] Walsh CT, Fisher SL, Park IS, Prahalad M, Wu Z. Chem Biol. 1996; 3:21. [PubMed: 8807824] Healy VL, Lessard IAD, Roper DI, Knox JR, Walsh CT. Chem Biol. 2000; 7:R109. [PubMed: 10801476]
- Woodford N. J Med Microbiol. 1998; 47:849. [PubMed: 9788808] Pootoolal J, Neu J, Wright GD. Annu Rev Pharmacol Toxicol. 2002; 42:381. [PubMed: 11807177] Courvalin P. Clin Infect Dis. 2006; 42:S25. [PubMed: 16323116]
- Reynolds PE, Snaith HA, Maguire AJ, Dutka-Malen S, Courvalin P. Biochem J. 1994; 301:5. [PubMed: 8037690]
- Abad a Pati o L, Courvalin P, Perichon B. J Bacteriol. 2002; 184:6457. [PubMed: 12426332]
- McKessar SJ, Berry AM, Bell JM, Turnidge JD, Paton JC. Antimicrob Agents Chemother. 2000; 44:3224. [PubMed: 11036060]
- van Wageningen AA, Kirkpatrick PN, Williams DH, Harris BR, Kershaw JK, Lennard NJ, Jones M, Jones SJM, Solenberg P. J Chem Biol. 1998; 5:155.
- Boger DL. Med Res Rev. 2001; 21:356. [PubMed: 11579438] Crowley BM, Boger DL. J Am Chem Soc. 2006; 128:2885. [PubMed: 16506767] Xie J, Pierce JG, James RC, Okano A, Boger DL. J Am Chem Soc. 2011; 133:13946. [PubMed: 21823662] Xie J, Okano A, Pierce JG, James RC, Stamm S, Crane CM, Boger DL. J Am Chem Soc. 2012; 134:1284. [PubMed: 22188323] Okano A, James RC, Pierce JG, Xie J, Boger DL. J Am Chem Soc. 2012; 134:8790. [PubMed: 22568755] James RC, Pierce JG, Okano A, Xie J, Boger DL. ACS Chem Biol. 2012; 7:797. [PubMed: 22330049] See also Boger DL, Miyazaki S, Kim SH, Wu JH, Loiseleur O, Castle SL. J Am Chem Soc. 1999; 121:3226. Boger DL, Miyazaki S, Kim SH, Wu JH, Castle SL, Loiseleur O, Jin Q. J Am Chem Soc. 1999; 121:10004. Boger DL, Kim SH, Miyazaki S, Strittmatter H, Weng JH, Mori Y, Rogel O, Castle SL, McAtee JJ. J Am Chem Soc. 2000; 122:7416. Boger DL, Kim SH, Mori Y, Weng JH, Rogel O, Castle SL, McAtee JJ. J Am Chem Soc. 2001; 123:1862. [PubMed: 11456806] Crowley BM, Mori Y, McComas CC, Tang D, Boger DL. J Am Chem Soc. 2004; 126:4310. [PubMed: 15053621] Garfunkle J, Kimball FS, Trzupek JD, Takazawa S,

- Shimamura H, Tomishima M, Boger DL. *J Am Chem Soc.* 2009; 131:16036. [PubMed: 19839632] Shimamura H, Breazzano SP, Garfinkle J, Kimball FS, Trzupek JD, Boger DL. *J Am Chem Soc.* 2010; 132:7776. [PubMed: 20469945] Breazzano SP, Boger DL. *J Am Chem Soc.* 2011; 133:18495. [PubMed: 21991993]
11. McAtee JJ, Castle SL, Jin Q, Boger DL. *Bioorg Med Chem Lett.* 2002; 12:1319. [PubMed: 11965380] McComas CC, Crowley BM, Hwang I, Boger DL. *Bioorg Med Chem Lett.* 2003; 13:2933. [PubMed: 14611861]
12. Crane CM, Boger DL. *J Med Chem.* 2009; 52:1471. [PubMed: 19209892] Crane CM, Pierce JG, Leung SSF, Tirado-Rives J, Jorgensen WL, Boger DL. *J Med Chem.* 2010; 53:7229. [PubMed: 20853900]
13. McComas CC, Crowley BM, Boger DL. *J Am chem Soc.* 2003; 125:9314. [PubMed: 12889959] Okano A, James RC, Pierce JG, Xie J, Boger DL. *J Am Chem Soc.* 2012; 134:8790. [PubMed: 22568755]
14. Pinchman JR, Boger DL. *J Med Chem.* 2013; 56:4116. [PubMed: 23617725]
15. Good VM, Gwynn MN, Knowles DJC. *J Antibiot.* 1990; 43:550. [PubMed: 2113517]
16. Harris CM, Kannan R, Kopecka H, Harris TM. *J Am Chem Soc.* 1985; 107:6652.
17. Boger DL, Miyazaki S, Kim SH, Wu JH, Castle SL, Loiseleur O, Jin Q. *J Am Chem Soc.* 1999; 121:10004.
18. Nieto M, Perkins HR. *Biochem J.* 1971; 124:845. [PubMed: 4331859] Nieto M, Perkins HR. *Biochem J.* 1971; 123:773. [PubMed: 5124385] Perkins HR. *Biochem J.* 1969; 111:195. [PubMed: 5763787]

Figure 1.
Vancomycin and vancomycin aglycon analogues.

Figure 2.

(a) $(\text{HO})_4\text{B}_2$ (3 eq), X-Phos-Pd-G2 (0.3 eq), KOAc (3 eq), X-Phos (0.6 eq), EtOH, 60 °C, 6 h, 19% **7**. (b) CuCl_2 , MeOH/ H_2O (60 °C, 2 h) then TFA/ CH_2Cl_2 , (25 °C, 20 min), 52% (two steps) $R^1 = R^2 = \text{H}$, $R^3 = \text{Cl}$, $R^4 = \text{H}$.

Vancomycin Analogues**Table 1**

Compound	R ¹	R ²	R ³
1	Sugar	Cl	Cl
2	H	Cl	Cl
3	H	H	Cl
4	H	Cl	H
5	H	H	H

Table 2

Binding and Antimicrobial Properties.

Compd	MIC (μg/mL)	Association constant for N,N'-Ac ₂ -L-Lys-D-Ala-X				
		K_{ap} M ⁻¹ D-Ala (×10 ⁵)	$\Delta\Delta G_b^{obs,b}$	K_{ap} M ⁻¹ D-Ser (×10 ³)	K_{ap} M ⁻¹ Gly (×10 ⁴)	K_{ap} M ⁻¹ D-Phe (×10 ²)
1	1.25	1.8				
2	1.25	1.4	-	3.3	1.0	9.1
3	10	0.38	0.77	4	0.49	9
4	5	0.68	0.42			
5	20	0.18	1.21			

^aVancomycin-sensitive *Staphylococcus aureus* (ATCC 25923).

^bThe free energy of binding ($\Delta\Delta G_b$) was tabulated from the experimentally determined K_a using the equation $\Delta\Delta G_b = RT\ln K$, where $K = \frac{1}{K_a} \times \frac{1}{K_a^X}$. K_a is the association constant for the complex of **2** with N,N'-Ac₂-L-Lys-D-Ala-D-Ala; ^X K_a is the association constant for the complex of compound **X** with N,N'-Ac₂-L-Lys-D-Ala-D-Ala.